Exscientia plc (EXAI) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Oxford, United Kingdom. El CEO actual es David Hallett.
EXAI tiene fecha de IPO 2021-10-01, 483 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $633.18M.
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
